Legend Biotech Results Presentation Deck

6 Out-licensing Deal with Novartis on CAR-T Therapies Targeting DLL3 Legend announced on Nov 13, 2023 an exclusive, global license agreement with Novartis to advance certain DLL3-targeted CAR-T therapies, including LB2102, an investigational therapy for small cell lung cancer. AN UPFRONT PAYMENT $100M ELIGIBLE MILESTONE PAYMENTS up to POTENTIAL APPLICATION OF T-Charge™ Platform of Novartis FOR MANUFACTURING $1.01B This presentation is for investor relations purposes only - Not for product promotional purposes Plus Tiered Royalties on Net Sales DLL3 DEVELOPMEMT AND COSTS → Legend to conduct Ph1 for LB2102 in the US Novartis to conduct all other development for the licensed products LEGEND BIOTECH

View entire presentation